Quantcast

Novo Nordisk: Tresiba Shows Improved Blood Sugar Control Versus Insulin Toujeo


Shutterstock photo


(RTTNews.com) - Novo Nordisk Canada Inc. reported that a large real-world evidence study which included more than 4,000 adults with type 2 diabetes who were starting basal insulin for the first time, comparing the effectiveness of Tresiba (insulin degludec injection) versus Toujeo (insulin glargine U300) showed that after six months those treated with Tresiba had significantly lower HbA compared to those treated with Toujeo. As a secondary endpoint, there was a 30 percent lower rate of hypoglycemic episodes with Tresiba compared to Toujeo.

The company said the real world study also showed in another secondary endpoint that people treated with Tresiba were more likely to stay on their treatment. Those treated with Toujeo had a 37 percent higher rate of discontinuing treatment after two years.


Read the original article on RTTNews (http://www.rttnews.com/2907764/novo-nordisk-tresiba-shows-improved-blood-sugar-control-versus-insulin-toujeo.aspx)


For comments and feedback: contact editorial@rttnews.com




This article appears in: World Markets , Stocks , Economy
Referenced Symbols: NVO


More from RTT News

Subscribe






See All RTT news









Research Brokers before you trade

Want to trade FX?